News
SILO
1.840
+2.79%
0.050
Weekly Report: what happened at SILO last week (1102-1106)?
Weekly Report · 2d ago
Silo Pharma, Inc. Enters into Securities Purchase Agreements for $815,000 Private Placement
NASDAQ · 4d ago
Silo Pharma Completes Private Placement to Fund Operations
TipRanks · 4d ago
Weekly Report: what happened at SILO last week (1026-1030)?
Weekly Report · 11/02 09:37
Weekly Report: what happened at SILO last week (1019-1023)?
Weekly Report · 10/26 09:37
Weekly Report: what happened at SILO last week (1012-1016)?
Weekly Report · 10/19 09:37
Silo Pharma Acquires Software Assets Through Equity Issuance
TipRanks · 10/14 21:02
Silo Pharma Agrees To Acquire Software And Related IP From Larry King, Issues 150,000 Shares In Consideration
Benzinga · 10/14 20:35
Weekly Report: what happened at SILO last week (1005-1009)?
Weekly Report · 10/12 09:39
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/06 21:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/05 12:05
Weekly Report: what happened at SILO last week (0928-1002)?
Weekly Report · 10/05 09:39
Silo Pharma Acquires IP Assets in Strategic Agreement
TipRanks · 10/02 20:57
Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting; To Buy Software And Intellectual Property From Norsight Consulting
Benzinga · 10/02 20:42
Silo Pharma’s QwikAgents expands AI agent platform with Nvidia model support
TipRanks · 09/30 13:00
Silo Pharma's QwikAgents Subsidiary Expands AI Agent Platform With New Client, To Support Client-Provided Nvidia API Keys, Adds Hermes Agent Runtime
Benzinga · 09/30 12:53
Weekly Report: what happened at SILO last week (0921-0925)?
Weekly Report · 09/28 09:37
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 09/25 21:05
Weekly Report: what happened at SILO last week (0914-0918)?
Weekly Report · 09/21 09:37
Biotech Stocks In Focus - IMCC +245%, XRTX +12%, SILO, BFRI
NASDAQ · 09/18 19:27
More
Webull provides a variety of real-time SILO stock news. You can receive the latest news about Silo Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.